GlassScriptPhysician profile
Michael J Wells
NPI 1831482454
$2,528.01
in general payments reported to CMS, 2019-2025
30 companies · $104 in 2025
The $104 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $161 · 2020: $279 · 2021: $639 · 2022: $736 · 2023: $469 · 2024: $140 · 2025: $104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $713.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $713.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $592.16 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $328.96 | 2019-2024 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $286.58 | 2019-2023 | Shingrix, Arexvy, Trelegy Ellipta |
| Amgen INC. | $208.29 | 2020-2023 | Aimovig |
| Abiomed | $125.00 | 2022 | |
| Alexion Pharmaceuticals, INC. | $109.99 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $106.15 | 2019-2024 | Airsupra |
| Amarin Pharma, INC. | $94.73 | 2020-2022 | |
| Exact Sciences Corporation | $93.76 | 2023-2024 | Cologuard Collection Kit |
| Stryker Corporation | $61.89 | 2025 | Flowtriever |
| Kowa Pharmaceuticals America, INC. | $49.84 | 2020-2021 | |
| Pfizer INC. | $44.68 | 2020-2024 | |
| Lilly USA, LLC | $42.21 | 2019-2024 | Mounjaro |
| Janssen Pharmaceuticals, INC | $41.57 | 2020-2022 | |
| Astellas Pharma US INC | $40.36 | 2019-2023 | Myrbetriq |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $36.51 | 2022 | |
| Dexcom, INC. | $28.49 | 2023 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $27.69 | 2022 | |
| Esperion Therapeutics, INC. | $27.30 | 2021 | |
| Sanofi Pasteur INC. | $25.73 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $23.41 | 2019-2020 | |
| Axsome Therapeutics, INC. | $20.60 | 2023 | Sunosi |
| Allergan, INC. | $16.71 | 2020 | |
| Nestle Healthcare Nutrition INC. | $15.89 | 2021 | |
| Amneal Pharmaceuticals LLC | $15.43 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.97 | 2020 | |
| Novartis Pharmaceuticals Corporation | $13.58 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $12.80 | 2022 | |
| Radius Health, INC. | $11.55 | 2021 | |
| Lifescan, INC. | $11.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Wells listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.